Bamco Inc. NY Grows Stock Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Bamco Inc. NY boosted its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 53.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 752,886 shares of the company's stock after purchasing an additional 263,500 shares during the period. Bamco Inc. NY owned about 2.69% of Establishment Labs worth $34,685,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Barclays PLC boosted its holdings in shares of Establishment Labs by 9,643.3% in the third quarter. Barclays PLC now owns 31,471 shares of the company's stock worth $1,362,000 after buying an additional 31,148 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Establishment Labs in the fourth quarter worth approximately $12,898,000. Raymond James Financial Inc. bought a new stake in shares of Establishment Labs during the 4th quarter valued at $5,494,000. KLP Kapitalforvaltning AS bought a new stake in shares of Establishment Labs during the 4th quarter valued at $161,000. Finally, Swiss National Bank increased its stake in shares of Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after purchasing an additional 1,000 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Price Performance

Shares of NASDAQ ESTA traded down $0.79 during mid-day trading on Friday, reaching $34.01. The company's stock had a trading volume of 485,256 shares, compared to its average volume of 465,850. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $60.12. The stock has a fifty day moving average of $34.83 and a two-hundred day moving average of $38.57. The firm has a market capitalization of $981.05 million, a PE ratio of -13.18 and a beta of 0.73.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.13. The firm had revenue of $41.38 million for the quarter, compared to analysts' expectations of $41.15 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The company's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.58) earnings per share. As a group, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ESTA. Stephens reiterated an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. Needham & Company LLC began coverage on Establishment Labs in a research note on Monday, April 14th. They set a "hold" rating for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $57.40.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.